These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

927 related items for PubMed ID: 23048051

  • 1. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
    Ahn JM, Park DW, Kim YH, Song H, Cho YR, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Han S, Lee SY, Lee BK, Cho JH, Yang TH, Lee NH, Yang JY, Park JS, Shin WY, Kim MH, Bae JH, Kim MK, Yoon J, Park SJ.
    Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
    [Abstract] [Full Text] [Related]

  • 2. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB.
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [Abstract] [Full Text] [Related]

  • 3. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS, Popma JJ, ENDEAVOR IV Investigators.
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [Abstract] [Full Text] [Related]

  • 4. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE, ENDEAVOR IV Investigators.
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [Abstract] [Full Text] [Related]

  • 5. Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.
    Kim U, Kim DK, Seol SH, Yang TH, Kim DK, Kim DI, Kim DS, Lee SH, Hong GR, Park JS, Shin DG, Kim YJ, Cho YK, Kim HS, Nam CW, Hur SH, Kim KB.
    Clin Cardiol; 2010 Jun; 33(6):340-4. PubMed ID: 20556803
    [Abstract] [Full Text] [Related]

  • 6. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B, Yang Y, Yuan Z, Du Z, Wong SC, Généreux P, Lu S, RESOLUTE China RCT Investigators.
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [Abstract] [Full Text] [Related]

  • 7. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ, Park DW, Kim WJ, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ.
    Catheter Cardiovasc Interv; 2013 Jun 01; 81(7):1106-14. PubMed ID: 22899589
    [Abstract] [Full Text] [Related]

  • 8. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
    Lee JY, Park DW, Kim YH, Ahn JM, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Yang TH, Lee BK, Lee NH, Yang JY, Shin WY, Park HS, Kim KS, Hur SH, Lee SY, Park JS, Choi YS, Lee SU, Her SH, Park SJ.
    Circ Cardiovasc Interv; 2014 Jun 01; 7(3):322-9. PubMed ID: 24823426
    [Abstract] [Full Text] [Related]

  • 9. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ, Leon MB, Ball MW, Bajwa HS, Sketch MH, Coleman PS, Stoler RC, Papadakos S, Cutlip DE, Mauri L, Kandzari DE, ENDEAVOR IV Investigators.
    JACC Cardiovasc Interv; 2013 Apr 01; 6(4):325-33. PubMed ID: 23523453
    [Abstract] [Full Text] [Related]

  • 10. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT, Sun H, Zhang DP, Xu L, Ni ZH, Xia K, Liu Y, Chi YH, He JF, Li WM, Wang HS, Wang LF, Yang XC.
    Coron Artery Dis; 2014 Aug 01; 25(5):405-11. PubMed ID: 24584031
    [Abstract] [Full Text] [Related]

  • 11. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ, ENDEAVOR III Investigators.
    JACC Cardiovasc Interv; 2009 Dec 01; 2(12):1199-207. PubMed ID: 20129546
    [Abstract] [Full Text] [Related]

  • 12. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2013 Aug 01; 6(8):777-89. PubMed ID: 23968698
    [Abstract] [Full Text] [Related]

  • 13. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE, Leon MB, Meredith I, Fajadet J, Wijns W, Mauri L.
    JACC Cardiovasc Interv; 2013 May 01; 6(5):504-12. PubMed ID: 23602459
    [Abstract] [Full Text] [Related]

  • 14. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB.
    JACC Cardiovasc Interv; 2009 Oct 01; 2(10):967-76. PubMed ID: 19850257
    [Abstract] [Full Text] [Related]

  • 15. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, te Riele JA, SPIRIT II Investigators.
    JACC Cardiovasc Interv; 2009 Dec 01; 2(12):1190-8. PubMed ID: 20129545
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
    Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, Ibrahim T, Fusaro M, Ott I, Schömig A, Laugwitz KL, Mehilli J, Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators.
    Circulation; 2011 Aug 02; 124(5):624-32. PubMed ID: 21768546
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May 02; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.